minretumomab minretumomab minretumomab (cc49) is a mouse monoclonal antibody that was designed for the treatment of cancers that express the tag-72 antigen. this includes breast, colon, lung, and pancreatic cancers. apparently, it never got past phase i clinical trials for this purpose. minretumomabmonoclonal antibodytypewhole antibodysourcemousetargettag-72clinical dataother namescc49atc codev09ix03 (who) (125i radiolabelled)identifierscas number195189-17-4 nchemspidernoneunii235435ch6l ny (what is this?) (verify) derivatives a wide range of derivatives has been used in pharmaceutical research. examples include chimeric and humanized minretumomab, as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase. radiopharmaceuticals iodine (125i) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as ca 72-4. radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. iodine (131i) and lutetium (177lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in phase i and ii clinical trials.